ScreenPoint Medical

ScreenPoint Medical is a leader in AI-powered breast imaging diagnostics, with its Transpara platform being one of the most clinically validated solutions in the sector. The company's core value proposition is increasing cancer detection rates while reducing radiologist workload, addressing critical industry challenges like staff shortages and rising screening volumes. Transpara is vendor-agnostic, integrated into major clinical workflows, and is backed by extensive peer-reviewed research, including participation in multiple randomized controlled trials (RCTs). The company is privately held, commercially deployed in over 30 countries, and is positioned at the forefront of the rapidly growing AI diagnostics market.

Deep learning-based AI engine (Transpara) for analyzing 2D and 3D mammograms. It is vendor-agnostic, provides cancer risk scores, and offers modular applications for detection, density assessment, and temporal comparison.

ScreenPoint operates in the competitive AI radiology market, with rivals ranging from pure-play AI companies (e.g., Lunit, Koios Medical) to divisions of large imaging equipment manufacturers (e.g., GE HealthCare, Siemens Healthineers). Its key competitive advantages are its extensive peer-reviewed publication record, participation in multiple RCTs (a rarity in the field), and its vendor-agnostic, workflow-integrated platform. Success hinges on maintaining clinical performance leadership and demonstrating superior real-world utility.